Table 2.

Prognostic Factors With Associated 3-Year Survival Rates Using Univariate Analysis

Variable	No. of Patients	Survival
		PFS			OS
		3-Year Rate (%)	95% CI	P	3-Year Rate (%)	95% CI	P
Performance status
0-1	55	67	52 to 78	.0012	73	59 to 83	.0003
2-4	25	36	18 to 54		35	15 to 56
Received first-line rituximab-based therapy				< .0001			.0001
No	21	21	7 to 42		33	14 to 53
Yes	59	70	57 to 81		73	58 to 83
Albumin				.03			.005
Normal	56	76	52 to 90		86	62 to 95
Low	23	50	36 to 62		53	38 to 65
CNS involvement				.02			.03
Absent	70	61	48 to 72		65	52 to 76
Present	10	30	7 to 58		40	12 to 67
Bone marrow involvement				.0007			.0006
Absent	57	66	51 to 77		71	57 to 81
Present	12	18	3 to 44		18	3 to 44
> 1 extranodal site				.06			.03
No	50	64	48 to 76		72	57 to 82
Yes	28	42	24 to 59		43	23 to 61

NOTE. The 3-year PFS and OS by Kaplan-Meier analysis are reported with their associated 95% CIs.

Abbreviations: PFS, progression-free survival; OS, overall survival.